The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceuticals, an AI-driven drug discovery platform trading over 100% below analyst consensus with multiple developmental milestones approaching.
Axe note: Gene editing, cloud restructuring, and AI drug discovery offer tangible growth stories worth watching.